In late 2024, Pfizer withdrew voxelotor (Oxbryta) from the market globally after concluding the risks outweighed the benefits. ASH Research Collaborative+1
That decision hit patients and clinicians hard—because many people had built their routine around it.
New real-world analysis: limited benefit, no clear harm signal
A more recent independent look using real-world electronic health record data (10,000+ patients, with a smaller voxelotor group) reported:
-
no significant decrease in pain crises compared to other disease-modifying therapies,
-
small improvements in hemoglobin and reticulocyte counts,
-
and no clear indicator of harm in the outcomes they analyzed. ASH Research Collaborative
That doesn’t undo the withdrawal—but it does help explain why this topic remains complicated and emotional: different datasets can highlight different risks/benefits.
If you or your loved one was on voxelotor
Here’s what we recommend from a practical standpoint:
-
Don’t stop or change meds without a prescriber.
-
Ask your hematology team:
-
“What’s our replacement plan?”
-
“How do we reduce crisis risk during transitions?”
-
“Do we need extra labs or follow-up visits?”
-
-
If you experienced worsening symptoms after stopping, document:
-
dates, ER visits, pain crisis frequency, transfusions, lab trends.
-
Treatment conversations to revisit
Many patients will be discussing combinations of:
-
hydroxyurea,
-
transfusion strategies,
-
newer therapies and clinical trials (depending on eligibility),
-
and non-medication supports (hydration plans, pain plans, trigger management).
Oklahoma-specific reminder
If your care access is limited by distance, scheduling, or insurance barriers, you’re not alone. We can help you:
-
organize records,
-
prepare questions,
-
identify support resources for travel/logistics.
Disclaimer: Educational content only; consult your healthcare team.